Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
It has been shown that bevacizumab has significant anti-tumor activity in patients with
recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against
malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics.
Patients will be treated with a combination of bevacizumab and vorinostat.